EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Preclinical Evaluation of a Lead Specific Chelator (PSC) Conjugated to Radiopeptides for 203Pb and 212Pb-Based Theranostics

Mengshi Li iD, Nicholas J Baumhover, Dijie Liu, Brianna S Cagle, Frédéric Boschetti, Guillaume Paulin, Dongyoul Lee iD, Zhiming Dai, Ephraim R Obot, Brenna M Marks, Ibrahim Okeil, Edwin A Sagastume und 4 weitere

Pharmaceutics · 26.01.2023 · 15 (2) · 414

DOI: 10.3390/pharmaceutics15020414 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 26.01.2023. Verfasst von Mengshi Li und 15 weiteren Autor:innen. Beteiligte Einrichtung: Viewpoint Molecular Targeting, Inc., 2500 Crosspark Road, Coralville, IA 52241, USA. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute, Holden Comprehensive Cancer Center Support Grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

203Pb and 212Pb have emerged as promising theranostic isotopes for image-guided α-particle radionuclide therapy for cancers. Here, we report a cyclen-based Pb specific chelator (PSC) that is conjugated to tyr3-octreotide via a PEG2 linker (PSC-PEG-T) targeting somatostatin receptor subtype 2 (SSTR2). PSC-PEG-T could be labeled efficiently to purified 212Pb at 25 °C and also to 212Bi at 80 °C. Efficient radiolabeling of mixed 212Pb and 212Bi in PSC-PEG-T was also observed at 80 °C. Post radiolabeling, stable Pb(II) and Bi(III) radiometal complexes in saline were observed after incubating [203Pb]Pb-PSC-PEG-T for 72 h and [212Bi]Bi-PSC-PEG-T for 5 h. Stable [212Pb]Pb-PSC-PEG-T and progeny [212Bi]Bi-PSC-PEG-T were identified after storage in saline for 24 h. In serum, stable radiometal/radiopeptide were observed after incubating [203Pb]Pb-PSC-PEG-T for 55 h and [212Pb]Pb-PSC-PEG-T for 24 h. In vivo biodistribution of [212Pb]Pb-PSC-PEG-T in tumor-free CD-1 Elite mice and athymic mice bearing AR42J xenografts revealed rapid tumor accumulation, excellent tumor retention and fast renal clearance of both 212Pb and 212Bi, with no in vivo redistribution of progeny 212Bi. Single-photon emission computed tomography (SPECT) imaging of [203Pb]Pb-PSC-PEG-T and [212Pb]Pb-PSC-PEG-T in mice also demonstrated comparable accumulation in AR42J xenografts and renal clearance, confirming the theranostic potential of the elementally identical 203Pb/212Pb radionuclide pair.

Schlagwörter

Stichwörter der Autor:innen

Bismuth-212Lead-203Lead-212chelatorsstabilitytheranostics

Autor:innen und Institutionen

  • Viewpoint Molecular Targeting, Inc., 2500 Crosspark Road, Coralville, IA 52241, USA.
  • CheMatech-MDT, 21000 Dijon, France.
  • Department of Physics and Chemistry, Korea Military Academy, Seoul 01805, Republic of Korea.
  • Department of Chemistry, The University of Iowa, Iowa City, IA 52240, USA.
  • Department of Radiology, Weill Cornell Medicine, New York, NY 10021, USA.
  • Department of Radiology, The University of Iowa, Iowa City, IA 52246, USA.

ORCID-Profile: Mengshi Li, Dongyoul Lee, Moustafa Gabr, F Christopher Pigge

Förderung

  • NCI NIH HHS
  • National Cancer Institute
  • Holden Comprehensive Cancer Center Support Grant

Zitieren

APA

Li, M., Baumhover, N. J., Liu, D., Cagle, B. S., Boschetti, F., Paulin, G., Lee, D., Dai, Z., Obot, E. R., Marks, B. M., Okeil, I., Sagastume, E. A., Gabr, M., Pigge, F. C., Johnson, F. L., & Schultz, M. K. (2023). Preclinical Evaluation of a Lead Specific Chelator (PSC) Conjugated to Radiopeptides for 203Pb and 212Pb-Based Theranostics. Pharmaceutics, 15(2), 414. https://doi.org/10.3390/pharmaceutics15020414

Vancouver

Li M, Baumhover NJ, Liu D, Cagle BS, Boschetti F, Paulin G, et al. Preclinical Evaluation of a Lead Specific Chelator (PSC) Conjugated to Radiopeptides for 203Pb and 212Pb-Based Theranostics. Pharmaceutics. 2023;15(2):414. doi:10.3390/pharmaceutics15020414

BibTeX
@article{Li2023,
  author = {Li, Mengshi and Baumhover, Nicholas J and Liu, Dijie and Cagle, Brianna S and Boschetti, Frédéric and Paulin, Guillaume and Lee, Dongyoul and Dai, Zhiming and Obot, Ephraim R and Marks, Brenna M and Okeil, Ibrahim and Sagastume, Edwin A and Gabr, Moustafa and Pigge, F Christopher and Johnson, Frances L and Schultz, Michael K},
  title = {Preclinical Evaluation of a Lead Specific Chelator (PSC) Conjugated to Radiopeptides for 203Pb and 212Pb-Based Theranostics},
  journal = {Pharmaceutics},
  year = {2023},
  volume = {15},
  number = {2},
  pages = {414},
  doi = {10.3390/pharmaceutics15020414}
}
Kostenlos starten →